Here's what you need to know about the headlines driving the markets.
Amazon has put tremendous pressure on traditional brick-and-mortar names and more recently, the trade war has become a headwind. But these names are posting robust growth and proving they can adapt.
Freeport-McMoRan is always going to be my first call on the health of copper.
Analyst Linda Bolton Weiser called Hasbro's deal for Entertainment One EPS accretive and a strategic match.
While noting the combination of China tariffs and recession fears may 'frighten some to the sidelines,' analysts at Raymond James cite the furniture maker's strong balance sheet with 'no funded debt,' rising dividends since 2013, and a still 'healthy U.S. consumer.'
Salesforce's Q2 performance was strong but its acquisitions muddy the year-over-year comparisons. Plus, its valuation gives its shares little margin for safety.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
It's all about interest rates and taxes for people and businesses.
Internal documents show Facebook employees knew that Cambridge was potentially misusing user data earlier than previously thought. Facebook says there were two separate incidents, however.